BidaskClub Upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Hold

BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a sell rating to a hold rating in a report issued on Saturday, January 6th.

Several other research analysts have also issued reports on RARE. Robert W. Baird reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 19th. Morgan Stanley reiterated an equal weight rating and issued a $71.00 price target (up from $69.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, October 6th. Raymond James Financial reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 15th. Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research note on Thursday, November 16th. Finally, Barclays raised their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an equal weight rating in a research note on Tuesday, December 5th. Nine research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $72.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $56.84 on Friday. The stock has a market cap of $2,714.49, a PE ratio of -8.15 and a beta of 1.83. Ultragenyx Pharmaceutical has a 12 month low of $43.14 and a 12 month high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.87). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. The firm’s revenue was up 81.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.64) earnings per share. equities analysts expect that Ultragenyx Pharmaceutical will post -7.31 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 7.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,474 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 248 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 7.6% during the 2nd quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 352 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 12.0% during the 2nd quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 365 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1.0% during the 2nd quarter. Principal Financial Group Inc. now owns 73,412 shares of the biopharmaceutical company’s stock valued at $4,559,000 after acquiring an additional 722 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.1% during the 2nd quarter. California Public Employees Retirement System now owns 39,100 shares of the biopharmaceutical company’s stock valued at $2,429,000 after acquiring an additional 800 shares during the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “BidaskClub Upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Hold” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/29/ultragenyx-pharmaceutical-rare-raised-to-hold-at-bidaskclub.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply